Holen Sie sich die Stockscreener-App
378.95
0.62%
2.34
Handel nachbörslich:
377.78
-1.17
-0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SYK?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$376.61
Offen:
$378.46
24-Stunden-Volumen:
1.50M
Relative Volume:
1.26
Marktkapitalisierung:
$144.88B
Einnahmen:
$23.82B
Nettoeinkommen (Verlust:
$2.92B
KGV:
50.19
EPS:
7.55
Netto-Cashflow:
$4.02B
1W Leistung:
+1.07%
1M Leistung:
-2.70%
6M Leistung:
-2.43%
1J Leistung:
+15.19%
1-Tages-Spanne:
$374.53
$379.33
1-Wochen-Bereich:
$373.72
$381.34
52-Wochen-Spanne:
$328.24
$406.19
Stryker Corp Stock (SYK) Company Profile
Firmenname
Stryker Corp
Sektor
Branche
Telefon
(269) 385-2600
Adresse
1941 STRYKER WAY, PORTAGE, MI
Vergleichen Sie SYK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.51B | 3.23B | 1.68 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 4.14B | 577.90M | 6.96 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Citigroup | Buy |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Outperform |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-22 | Hochstufung | Needham | Hold → Buy |
| 2024-01-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-25 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-11-01 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-28 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-07-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-13 | Eingeleitet | Truist | Hold |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-15 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-07-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-06-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-10-06 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-04-01 | Herabstufung | Goldman | Buy → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Hold |
| 2020-01-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2020-01-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-12-30 | Bestätigt | BTIG Research | Buy |
| 2019-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-30 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-16 | Eingeleitet | BTIG Research | Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Mkt Perform |
| 2018-04-27 | Bestätigt | Stifel | Buy |
Alle ansehen
Stryker Corp Aktie (SYK) Neueste Nachrichten
5 Revealing Analyst Questions From Stryker’s Q2 Earnings Call - Yahoo Finance
Perimeter Announces Preliminary Unaudited Revenues for the 2025 Second Quarter; Reduces Operating Costs by ~30% as Company Focuses on Commercial Sales Pipeline and Growth Opportunities - Benzinga
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital - Ortho Spine News
Stryker's (NYSE:SYK) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
A Quick Look at Today's Ratings for Stryker Corp(SYK.US), With a Forecast Between $407 to $456 - 富途牛牛
Massive Stryker Stock Sale by Director Ronda Stryker! - TipRanks
Stryker Corp To Go Ex-Dividend On September 30th, 2025 With 0.84 USD Dividend Per Share - 富途牛牛
Stryker Corp Director Sells 134,961 Shares Amid Market Volatility - AInvest
Stryker Corp(SYK.US) Director Sells US$75.29 Million in Common Stock - 富途牛牛
Fed. Circ. Affirms PTAB Ax Of Bone Fusion Device Patents - Law360
Berkshire Unit Keeps Win Over Two Stryker Joint-Plate Patents - Bloomberg Law News
Stryker declares an $0.84 per share quarterly dividend - Ortho Spine News
Stryker declares quarterly dividend of $0.84 per share - Investing.com
Stryker raises 2025 sales, earnings guidance again after strong quarter - Crain's Grand Rapids Business
Stryker Corporation (NYSE:SYK) Not Flying Under The Radar - 富途牛牛
Are Medical Stocks Lagging Stryker (SYK) This Year? - Yahoo Finance
What's Driving the Market Sentiment Around Stryker? - 富途牛牛
Truist Financial Keeps Their Hold Rating on Stryker (SYK) - The Globe and Mail
Citizens JMP reiterates Market Perform rating on Stryker stock after Q2 beat - Investing.com Canada
Citizens JMP reiterates Market Perform rating on Stryker stock after Q2 beat By Investing.com - Investing.com South Africa
Fund Update: Mesirow Financial Investment Management, Inc. added 43,487 shares of STRYKER ($SYK) to their portfolio - Quiver Quantitative
Truist Securities raises Stryker stock price target to $415 on solid results By Investing.com - Investing.com South Africa
Truist Securities raises Stryker stock price target to $415 on solid results - Investing.com
Truist Financial Maintains Stryker Corp(SYK.US) With Hold Rating, Raises Target Price to $415 - 富途牛牛
Stryker price target raised to $415 from $410 at Truist - TipRanks
What makes Stryker Corporation stock price move sharplyCapitalize on fast-moving stock opportunities - Jammu Links News
Does Stryker Corporation stock perform well during market downturnsIdentify undervalued stocks poised to rally - Jammu Links News
Why We're Not Concerned About Stryker Corporation's (NYSE:SYK) Share Price - 富途牛牛
Stryker Corporation (NYSE:SYK) Q2 2025 Earnings Call Transcript - Insider Monkey
Stryker Corp Reports Strong Q2 2025 Earnings Growth - The Globe and Mail
Stryker Corp’s Earnings Call Highlights Robust Growth - TipRanks
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Stryker (SYK) Raises Guidance As Sales Reach US$6 Billion In Strong Q2 - Yahoo Finance
Stryker (SYK) Analyst Rating Update: Wells Fargo Raises Price Ta - GuruFocus
Stryker (SYK) Receives Price Target Boost from Baird - GuruFocus
Stryker price target raised to $438 from $421 at UBS - TipRanks
Zimmer Biomet Holdings, Inc. shares fall 1.57% intraday as Stryker reports strong Q2 earnings. - AInvest
Stryker Remains on Pace to Benefit From a String of New Product Launches - Morningstar
Stryker lowers expected tariff impact to $175M - Yahoo Finance
Stryker price target raised to $450 from $436 at Baird - TipRanks
Stryker raises 2025 outlook amid 17.3% medical surgery and neurotechnology unit rise - Yahoo Finance
Needham Raises Price Target for Stryker (SYK) to $448, Maintains Buy Rating | SYK Stock News - GuruFocus
Why Stryker’s Stock is Gaining Momentum - TipRanks
Stryker Corp (SYK) Q2 2025 Earnings Call Highlights: Strong Growth Amid Supply Chain Challenges - Yahoo Finance
Stryker Corp (SYK) Q2 2025 Earnings Call Highlights: Strong Growth Amid Supply Chain Challenges By GuruFocus - Investing.com Canada
Stryker: Q2 Earnings Snapshot - Greenwich Time
Earnings call transcript: Stryker Q2 2025 beats EPS and revenue forecasts - Investing.com
Stryker shares tumble despite strong Q2 results and raised guidance By Investing.com - Investing.com South Africa
Stryker shares tumble despite strong Q2 results and raised guidance - Investing.com
Stryker (NYSE:SYK) Surprises With Q2 Sales But Stock Drops - Yahoo Finance
Stryker Lifts Guidance on Improving Tariff Outlook - 富途牛牛
Finanzdaten der Stryker Corp-Aktie (SYK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):